Cambrex Corporation

Cambrex Corporation
TypePrivate
IndustryPharmaceuticals
FoundedNew Jersey (1981)
HeadquartersEast Rutherford, NJ
Key people
Thomas Loewald, CEO
Number of employees
2,200+
Websitecambrex.com

Cambrex Corporation is a contract manufacturing organization in the pharmaceutical industry. The company has manufacturing facilities in the United States and Europe is headquartered in East Rutherford, NJ.

History

Cambrex was founded in 1979, following the acquisition of a chemical business from NL Industries by the Ennis Family. The company was initially known as CasChem before rebranding as Cambrex Corporation in 1987. It became listed on NASDAQ in same year and was listed on the NYSE in 1990.

During the 1990s and early 2000s, the company expanded into pharmaceutical manufacturing through a series of acquisitions of chemical and life sciences businesses. These transactions contributed to the development of its contract manufacturing activities.

In 2007, Cambrex divested its biologics manufacturing business to Lonza Group, focusing thereafter on small molecule pharmaceutical services.[1]

In 2008, Cambrex acquired Prosyntest (now Cambrex Tallinn),[2] and Steve Klosk was appointed CEO, while continuing to serve as president.[3]

In 2010, Cambrex acquired IEP, which became part of its operations under the name Cambrex IEP.[4]

In 2019, Cambrex acquired Avista Pharma Solutions for $252m.[5] Later that year, the company was acquired by an affiliate of funds advised by Permira, resulting in a transition to private ownership.[6]

In 2020, Cambrex completed expansions at its facilities in Edinburgh, United Kingdom, and Durham, North Carolina.[7][8] Thomas Loewald was appointed chief executive officer in September 2020.[9]

In 2022, Cambrex acquired Q1 Scientific, based in Waterford, Ireland.[10]

In 2023, Cambrex acquired the Waltham-headquartered chemical process development services provider, Snapdragon Chemistry.[11]

In 2024, Cambrex expanded Q1 Scientific’s operations with an additional stability storage facility in Durham, North Carolina.[12]

In 2025, Cambrex sold its large-scale drug product business unit to Noramco, including facilities in Whippany, NJ and Mirabel, Quebec.[13]

References

  1. ↑ "CDMO | News | Sale of Bio Business Completed". Cambrex. 2007-02-06. Retrieved 2021-10-04.
  2. ↑ "CDMO | News | Cambrex Signs Agreement to Acquire Prosyntest AS". Cambrex. 2008-01-07. Retrieved 2021-10-04.
  3. ↑ "CDMO | News | Steven Klosk Appointed as President and CEO". Cambrex. 2008-05-15. Retrieved 2021-10-04.
  4. ↑ "CDMO | News | Cambrex Acquires IEP GmbH". Cambrex. 2010-03-22. Retrieved 2021-10-04.
  5. ↑ "Cambrex acquires Avista for $252m, becomes integrated CDMO". outsourcing-pharma.com. 21 November 2018. Retrieved 2020-05-18.
  6. ↑ "CDMO | News | Completed Acquisition by The Permira Funds". Cambrex. 2019-12-04. Retrieved 2021-09-29.
  7. ↑ "CDMO | News | Expansion Completed at Edinburgh Facility". Cambrex. 2020-10-12. Retrieved 2021-10-04.
  8. ↑ "CDMO | News | Biopharmaceutical Expansion at Durham, NC". Cambrex. 2020-04-07. Retrieved 2021-10-04.
  9. ↑ "CDMO | News | Announcement of Thomas Loewald as CEO". Cambrex. 2020-06-18. Retrieved 2021-10-04.
  10. ↑ "Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific | News". Cambrex. Retrieved 2025-06-25.
  11. ↑ "Cambrex Completes Acquisition of Snapdragon Chemistry | News". Cambrex. Retrieved 2025-06-25.
  12. ↑ "Cambrex Opens Stability Storage Facility in North Carolina | News". Cambrex. Retrieved 2025-06-25.
  13. ↑ "Cambrex Announces Sale of Drug Product Business Unit | News". Cambrex. Retrieved 2025-06-25.
  • Official website
    • Historical business data for Cambrex Corporation:
    • SEC filings
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.